This Biospecimens, Pathology, and Clinical Database Core (Core A) will not only furnish essential services for the individual projects by managing patient data, safety, and samples, but it will provide a link between clinical data and research outcomes and interphase with the Biostatistics and Bioinformatics Core to allow for formal interactions between existing datasets to develop relational networks. It will accomplish its goals by integrating with and building upon existing, successful infrastructure housed at the Mayo Clinic, making the Core A an efficient, integral component of this SPORE. The significant patient referral base and clinical practice at the Mayo Clinic (>10,000 patient visits annually with multiple myeloma and related conditions) will allow substantial patient recruitment to the clinical trials and translational studies in this Mayo SPORE in multiple myeloma. The already extant 8000+ bone marrow samples in our Biospecimens Core make Aims in SPORE projects 3 and 4 possible. The on-going initiative of collecting data and research specimens from additional myeloma patients will feed into all SPORE projects and make Development Research and Career Development Award Programs possible.
The Aims of the Core are: 1, to provide support for collection, transport, processing and storage of samples; 2, to supply the data system infrastructure to track all SPORE patients and samples; 3, to provide coordination and oversight of distribution of samples to SPORE investigators; and 4, to generate and complete data-mining projects using existing clinical data, including exploration of flow-cytometry, FISH, and GEP. This Core provides a mechanism of consistent and compatible data handling, thereby facilitating management of collected data and integration with data from existing Mayo resources. Areas of data support include database development, data form development and processing, quality control, data collection and entry, and data archiving. This Core is unique not only in its scope and potential, but also in that it will be built on existing (but currently unfunded) tissue banking facilities and processes at the Mayo Clinic in Rochester and in Arizona, guaranteeing successful performance. Finally, Core A will interface with the clinical research components of other SPORE grantees and cancer centers to facilitate multi-institutional clinical research arising out of national myeloma research efforts.

Public Health Relevance

The strengths of the Biospecimens/Bioinformatics Core are our collaboration with each of the projects, our close integration with the Biostatistics/Bioinformatics Core and the diverse experience or our members. This core builds upon the innovative and time-tested procedures and systems established with our Comprehensive Cancer Center and by leaders in the field of multiple myeloma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA186781-04
Application #
9548989
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Mayo Clinic, Arizona
Department
Type
DUNS #
153665211
City
Scottsdale
State
AZ
Country
United States
Zip Code
85259
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Go, Ronald S; Rajkumar, S Vincent (2018) How I manage monoclonal gammopathy of undetermined significance. Blood 131:163-173
Kyle, Robert A; Larson, Dirk R; McPhail, Ellen D et al. (2018) Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clin Proc 93:739-746
Calcinotto, Arianna; Brevi, Arianna; Chesi, Marta et al. (2018) Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun 9:4832
Facon, Thierry; Dimopoulos, Meletios A; Dispenzieri, Angela et al. (2018) Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131:301-310
Sidana, Surbhi; Tandon, Nidhi; Dispenzieri, Angela et al. (2018) Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia 32:1421-1426
Gertz, Morie A (2018) Acute hyperviscosity: syndromes and management. Blood 132:1379-1385
Sidiqi, M Hasib; Aljama, Mohammed A; Muchtar, Eli et al. (2018) Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biol Blood Marrow Transplant 24:2157-2159
Kumar, S K; Dispenzieri, A; Fraser, R et al. (2018) Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 32:986-995
(2018) Multiple myeloma: 2018 update on diagnosis, risk?stratification, and management Am J Hematol 93:981-1114

Showing the most recent 10 out of 95 publications